MCM
BSX icon

McGlinn Capital Management’s Boston Scientific BSX Stock Holding History

McGlinn Capital Management’s Portfolio BSX Stock Details BSX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-19,300
Closed -$227K – 58
2013
Q3 		$227K Hold
19,300
– – 0.55% 42
2013
Q2 		$179K Buy
+19,300
New +$164K 0.49% 46

Other funds holding BSX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BG
Bollard Group Boston, Massachusetts $3.29B AUM 4.86% 1-Year Est. Return
Diamond Hill Capital Management
Diamond Hill Capital Management Columbus, Ohio $12.5B AUM 7.49% 1-Year Est. Return

McGlinn Capital Management's BSX Position: Q4 2013 in Review

McGlinn Capital Management sold out of Boston Scientific (BSX) in Q4 2013, closing a stake of 19,300 shares — an estimated $227K sold.

McGlinn Capital Management first reported a position in BSX in Q2 2013 and held it in 2 quarters. The position peaked at $227K in Q3 2013. 452 funds tracked by Wall St. Rank hold BSX as of Q4 2013.

  • McGlinn Capital Management reported no remaining Boston Scientific position as of Q4 2013 after selling out during the quarter.
  • McGlinn Capital Management sold 19,300 Boston Scientific shares in Q4 2013, an estimated $227K.
  • McGlinn Capital Management first reported a position in Boston Scientific in Q2 2013 and held it in 2 quarters.
  • McGlinn Capital Management's Boston Scientific position peaked at $227K in Q3 2013.
  • 452 funds tracked by Wall St. Rank held Boston Scientific as of Q4 2013.

Based on McGlinn Capital Management's 13F filing for Q4 2013, filed 31 Jan 2014.